authority failure are given a specific diagnostic test to determine whether they have preexisting left ventricular dysfunction and depending on the outcome of that diagnostic tests are given are given one of two specifically specified treatment protocols one is the administration of all in addition to other things that are done for these gravely ill children to give them twenty parts per million of inhaled nitric oxide that was in the that was in the prior art and the discovery in this case that came out of the i not twenty two study was that neonates with the parts of respiratory failure that have preexisting because as justice prior explained for the court in mayo diagnostic claims that merely quote inform the audience about certain laws of nature while quote trusting the audience to use those laws crow pria plea are directed to the law of nature but at the opinion goes on to say a patent claiming a treatment method quotes such as a new way of using it to be existing drugs mayo and myriad and and alice that is if you ask you know other words the difference between your honour's hypothetical and this one is the fundamental difference that this court has repeatedly recognized between a patent claim that recites a discovery and trusts the relevant person of ordinary skill in the yard to use the knowledge the information conveyed in the claim in the best consider altering the treatment said instead alter the treatment to give more or less depending on the blood levels that would then have been patton eligible i think that would have been patent eligible stronger case because using false and affirmative proactive step that is the testing for preexisting l v that didn't exist male where everybody was being treated with  think that the import of justice prior's of opinion in mayo in which he makes clear that he is not addressing the latter situation that would leave much of mayo and i thought wouldn't it be but the first reason is there's a huge difference in preemptive scope the the main concern that mayo was concerned about is patenting the discovery patenting the observation pre anybody from coming up with further treatments other for example other metabolite levels to take the actual example in mayo in this case if all that was being patented was the scientist any physician who did that in an attempt to come up with a different or more efficacious treatment regimen would be infringing the patent whereas here and in the in of all claims that had specific treatment steps there is nothing whatsoever that protects the spur bence the scientific community with coming up with other ways of helping neonates with i pods of respiratory failure and  is a form of judged like what you were describing in one of the three context and previous labs versus rocksand that is quote singling out a particular subset of patients for treatment may reflect a new and useful invention that is patent eligible despite the existence of prior art or prior to our patent disclosing the treatment method to patients generally but let me just speak well just to pursue this are you suggesting that the line is drawn depending on whether that particular that specificity is in the claim rather than in the disclosure that it's insufficient if it's in the specification in general but that if it's moved into the claim with then cross the barrier so the section one a one problem and move only into one of the three even try to understand their yeah so your lines were drawn our position is this and i think this is imbedded in the supreme court cases going at least back to front brothers that is there is a fundamental difference for one or one purposes between a claim that recites a do new discovery and leaves it to the discretion of practitioners how to apply that discovery and they claim that apply that new discovery for a specific new and useful and for example i think it's hard to read mail that i mean because mayo itself and in myriad an alice leave iran make clear that merely telling someone to apply the discovery it doesn't make it patent eligible and in a way that seems as though that's what the situation  well i think i think you can you identify the crux of the issue that was the crux of the dispute between the majority of the dissent in the recent vanda decision i think that might my understanding of mayo and frankly i think this circu understanding of mayo is that there is a difference between doing the here's a new discovery go ahead and apply it which just just prior explained just like einstein telling the operators  spirit of special relativity do the following x y and z the scope of preemption between those two things is vastly different and the nature of the claim that is the what this court has said over and over again looking at mayo is you get all of its diagnostic cases says look at the end result the beginning in the end of the process here is the same it's information it's  as your honor said in the genetic technologies versus myriad case quote the product of the method of the claim is information close quote it was not a new and useful way of applying the information similarly in the bracket case of this court the court said quote the claim recites nothing more than the abstract mental steps necessary to compare two different nucleotides sequences there was no element of the claim there was no aspect of the invention that said now go ahead and apply this in this new and useful way and that i understand is that distinction in the law and i think it's the distinction that has to be phrasing it is that what would be left of mayor there would be nothing more the point that the supreme court was making and they always just depend on how you draft of the coins you will get around mayo by grafting the claims the right way and yet mayo charges us not to let it turn on the draughtsman's are well it is true that you can't let something turn on the draughtsman's are any treatment step at a sufficient level of  high level of generality that it is not patterned eligible but i think what if one thinks about the conservative the reason for the judge made doctrine limiting the broad scope of one hundred one is a concern about preemption about preemption preempting further discovery and the difference between the claim that says here is an observed law of nature that they have consequences in the real world apply it accordingly is categorically different than a claim that says here is a new law of nature and with the with that new law of nature of you need to do the following integrated things you need to find this population you need to test this population in this way and then you need to selectively administer a treatment protocol the consequence of you know if you were a new treatment protocol  difference with respect between the claimant issue in this case and the claim that was held patent eligible subject matter in vanda is that in the end of the differential treatment involved with respect to a particular select conventional utterly nothing conventional about withholding one of the few life saving bets few life saving therapy there appease from a and e o date with hypoxic respiratory failure more conventional would be what was what was claimed and help patentable in vanda which is give them a lower dose the point here is that the difference between something that says if you do this test and you and if you find a particular result you would minister between twelve milligrams and below org if you find this you do something more dramatic and don't administer all suggest that if the claim in this case it said if you s sure i mean i think it large part were happy to rely on the briefing in this case but i did frenchmen are pissed fundamental position is that the court interpreted the d s i our claims in a way that contradicts their components quote in communication with the memory that receives signals and quote verifies one or more of gas identification gas concentration and that the gas has not expired but claim language and this relates to the construction of verification the claim language is about verifying the gas that is stored in the memory it does not require and indeed to my knowledge in my client's knowledge there is no although i think it's unusual to claim in action to claim not doing particular steps rather than doing that with respect to the relationship of the extent out for law i think it's worth looking at the i just a free points one goes directly i think to judge thanks question to me and first question to my friend which i think which i understand it begs the observation that well perhaps if withholding this drop this this w perhaps withholding this rug simply flows from the natural law itself i want to i want to explain why i think that's not a fair means for distinguishing between patentable and not patentable claims and in any event is not a correct act is not an accurate characterization of what in fact was necessarily discovered first of all if you discover something that helps you discover that aspirin helps headaches or chemotherapy helps cancer the most natural thing to do is to apply it but we don't deny patent eligibility on the grounds that the discovery of something new if applied is the most natural thing to in light of the discovery second of all withholding i and though which is one of the few means of treating these gravely ill the o mates is not the most obvious thing to do among the many other ways you could assuming the science clears this out and country to my friend's representation there would be nothing preemptive in this claim from  figuring out and demonstrating that you can just give a lower dosage you can separate out the dosing times you can administer the regular dose along with another product another therapeutic agent that mitigates the risk of l v all of those other things may turn out to be and efficacious way to balance somebody it is not the most obvious thing for a physician in th you who concludes if i don't give i end of this baby will die as a certainty in my medical judgment and so the this is simply not a case in which withholding flows from the natural law itself and finally with respect to my friends i'm sure patients about what would or would not amount to infringement of this claim the district judge didn't address infringement either direct or contributory or induced infringement with respect to this claim and presumably if this court reverses the determination of want to walk we will have a about whether or not if this and the step there is in fact an infringement and we think there is but it's not before this court thank you we thank both sides in the cases  next case for argument is eighteen one one seven to own a corporation versus